Interactions between neuroleptics and 5-HT(1A) ligands in preclinical behavioral models for antipsychotic and extrapyramidal effects

Psychopharmacology

Volumn 144, Issue 1, 1999, Pages 20-29

  Prinssen, Eric P M ^a   Kleven, Mark S ^a   Koek, Wouter ^a  

^a INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

Antipsychotic; Catalepsy; Dopamine D2 receptor; Extrapyramidal side effect; Intrinsic activity; Neuroleptic; Paw test; Rat; Schizophrenia; Serotonin 5 HT(1A) receptor

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; CLOZAPINE; HALOPERIDOL; LIGAND; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; N TERT BUTYL 3 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL] 2 PHENYLPROPIONAMIDE; NEUROLEPTIC AGENT; RISPERIDONE; SEROTONIN 1A AGONIST; SODIUM CHLORIDE; TROPAPRIDE;

ANIMAL EXPERIMENT; ARTICLE; CATALEPSY; CONTROLLED STUDY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG SCREENING; EXTRAPYRAMIDAL SYMPTOM; MALE; NONHUMAN; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; RAT; RECEPTOR INTRINSIC ACTIVITY; SCHIZOPHRENIA; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMALS; BEHAVIOR, ANIMAL; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HALOPERIDOL; NORTROPANES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, SEROTONIN; RISPERIDONE; SCHIZOPHRENIA;

EID: 0032977704     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002130050972     Document Type: Article

References (52)

1. 1A receptor antagonists on hippocampal 5-hydroxytryptamine levels: (S)-WAY100135, but not WAY100635, has partial agonist properties. Eur J Pharmacol 304:15-21
2. 1A receptor agonist properties of the antipsychotic, nemonapride: comparison with bromerguride and clozapine. Eur J Pharmacol 334: 141-147
3. Barnes NM, Costall B, Domeney AM, Gerrard PA, Kelly ME, Krahling H, Naylor RJ, Tomkins DM, Williams TJ (1991) The effects of umespirone as a potential anxiolytic and antipsychotic agent. Pharmacol Biochem Behav 40:89-96
4. Berendsen HHG, Broekkamp CLE, Pinder RM (1998) Mirtazapine enhances the effect of haloperidol on apomorphine induced climbing behaviour in mice and attenuates haloperidol induced catalepsy in rats. Psychopharmacology 135:284-289
5. Broekkamp CLE, Oosterloo SK, Berendsen HHG, van Delft AML (1988) Effect of metergoline, fenfluramine, and 8-OHDPAT on catalepsy induced by haloperidol or morphine. Naunyn-Schmiedeberg's Arch Pharmacol 338:191-195
6. Casey DE (1996) Extrapyramidal syndromes and new antipsychotic drugs: findings in patients and non-human primate models. Br J Psychiatry 168:32-39
7. Christensen AV (1985) Classification of neuroleptics: implications for tardive dyskinesia. Pol J Pharm Pharmacol 37:295-309
8. Christoffersen CL, Meltzer LT (1998) Reversal of haloperidol-induced extrapyramidal side effects in cebus monkeys by 8-hydroxy-2-(di-n-propylamino)tetralin and its enantiomers. Neuropsychopharmacology 18:399-402
9. Cools AR, Prinssen EPM, Ellenbroek BA (1995) The olfactory tubercle as a site of action of neuroleptics with an atypical profile in the paw test: effect of risperidone, prothipendyl, ORG 5222, sertindole and olanzapine. Psychopharmacology 119: 428-439
10. 1A receptor agonists: recent developments and controversial issues. Psychopharmacology 121:1-26
11. Ellenbroek BA (1993) Treatment of schizophrenia: a clinical and preclinical evaluation of neuroleptic drugs. Pharmacol Ther 57:1-78
12. Ellenbroek BA, Cools AR (1988) The paw test: an animal model for neuroleptic drugs which fulfils the criteria for pharmacological isomorphism. Life Sci 42:1205-1213
13. Ellenbroek BA, Peeters BW, Honig WM, Cools AR (1987) The paw test: a behavioural paradigm for differentiating between classical and atypical neuroleptic drugs. Psychopharmacology 93:343-348
14. Ellenbroek BA, Prinssen EPM, Cools AR (1994) The role of serotonin receptor subtypes in the behavioural effects of neuroleptic drugs. A paw test study in rats. Eur J Neurosci 6:1-8
15. Gerlach J, Peacock L (1995) New antipsychotics: the present status. Int Clin Psychopharmacol 10:39-48
16. 1A receptor agonists and antagonists: a comparison to adrenergic and dopaminergic neurons in rats. J Pharmacol Exp Ther 273:1032-1046
17. 1A agonists with potential anxiolytic properties. J Pharmacol Exp Ther 246:745-752
18. Hrib NJ, Jurcak JG, Huger FP, Errico CL, Dunn RW (1991) Synthesis and biological evaluation of a series of substituted N-alkoxyimides and N-alkoxyamides as potential atypical antipsychotic agents. J Med Chem 34:1068-1072
19. 1A receptor agonist, blocks haloperidol-induced catalepsy by an action on raphe nuclei medianus and dorsalis. Neuropharmacology 27:515-518
20. Jalfre M, Bucher B, Dorme N, Mocquet G, Porsolt RD (1983) Neuropharmacological profile of MD 790501, a new benzamide derivative. Arch Int Pharmacodyn 264:232-256
21. Kalkman HO, Neumann V, Nozulak J, Tricklebank MD (1998) Cataleptogenic effect of subtype selective 5-HT receptor antagonists in the rat. Eur J Pharmacol 343:201-207
22. Kato T, Hirose A, Ohno Y, Shimizu H, Tanaka H, Nakamura M (1990) Binding profile of SM-9018, a novel antipsychotic candidate. Jpn J Pharmacol 54:478-481
23. Kinon BJ, Lieberman JA (1996) Mechanisms of action of atypical antipsychotic drugs: a critical analysis. Psychopharmacology 124:2-34
24. 2 receptor antagonists to inhibit methylphenidate-induced behaviors in rats. Eur J Pharmacol 313:25-34
25. 1A receptors and their modulation of the activity of serotoninergic and dopaminergic neurones in rats. J Pharmacol Exp Ther 280:1241-1249
26. 2 receptors. Psychopharmacology 112:S40-S54
27. 2 antagonists on haloperidol-induced dyskinesias in squirrel monkeys: no evidence for reciprocal 5-HT-dopamine interaction. Psychopharmacology 97: 456-461
28. 2A/C antagonist, reverse haloperidol induced catalepsy in rats independently of striatal dopamine release. Psychopharmacology 131:57-63
29. McMillen BA, Scott SM, Davanzo EA (1988) Reversal of neuroleptic-induced catalepsy by novel aryl-piperazine anxiolytic drugs. J Pharm Pharmacol 40:885-887
30. 2 pKi values. J Pharmacol Exp Ther 251: 238-246
31. Neal-Beliveau BS, Joyce JN, Lucki I (1993) Serotonergic involvement in haloperidol-induced catalepsy. J Pharmacol Exp Ther 265:207-217
32. 1A receptors. Neuropharmacology 35:119-121
33. 1A receptors as a function of receptor: G-protein stoichiometry. Neuropharmacology 36:451-459
34. 1A agonists as neuroleptic agents. J Med Chem 39:1172-1188
35. 1A/D-2 ligands. Med Chem Res 7:76-86
36. Peuskens J (1995) Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Br J Psychiatry 166:712-726
37. Prinssen EPM, Ellenbroek BA, Stamatovic B, Cools AR (1993) The effects of haloperidol and raclopride in the paw test are influenced similarly by SCH 39166. Eur J Pharmacol 231:275-280
38. 2 receptors in the paw test, an animal model for the therapeutic efficacy and extrapyramidal side effects of neuroleptic drugs. Brain Res 673:283-289
39. Prinssen EPM, Kleven MS, Koek W (1996) Effects of dopamine antagonists in a two way active avoidance procedure in rats: interactions with 8-OH-DPAT, ritanserin, and prazosin. Psychopharmacology 128:191-197
40. 1A receptor agonist properties. Eur J Pharmacol 356:189-192
41. 1A-adrenergic affinity and a low potential for extrapyramidal effects. J Med Chem 37:1060-1062
42. 1a receptor agonists block prepulse inhibition of acoustic startle reflex. J Pharmacol Exp Ther 263:486-493
43. Scheel-Krüger J, Christensen A (1980) The role of gamma-aminobutyric acid in acute and chronic neuroleptic action. Adv Biochem Psychopharmacol 24:233-243
44. Seeger TF, Seymour PA, Schmidt AW, Zorn SH, Schulz DW, Lebel LA, McLean S, Guanowsky V, Howard HR, Lowe JA III, Heym J (1995) Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J Pharmacol Exp Ther 275:101-113
45. 1A agonists and partial agonists suppress conditioned avoidance responding in rats. Soc Neurosci Abstr 18:549
46. Sipes TA, Geyer MA (1995) 8-OH-DPAT disruption of prepulse inhibition in rats: reversal with (+) WAY 100,135 and localization of site of action. Psychopharmacology 117:41-48
47. Swerdlow NR, Braff DL, Taaid N, Geyer MA (1994) Assessing the validity of an animal model of deficient sensorimotor gating in schizophrenic patients. Arch Gen Psychiatry 51:139-154
48. Tallarida RJ, Murray RB (1987) Manual of pharmacological calculations with computer programs. Springer, New York
49. Wadenberg M-L, Ahlenius S (1991) Antipsychotic-like profile of combined treatment with raclopride and 8-OH-DPAT in the rat: enhancement of antipsychotic-like effects without catalepsy J Neural Transm 83:43-53
50. 1A autoreceptors by the local application of 8-OH-DPAT reverses raclopride-induced catalepsy in the rat. Neuropharmacology 34:495-499
51. 2 receptor mechanisms in the mediation of extrapyramidal motor functions in the rat. Pharmacol Biochem Behav 47:509-513
52. Winer BJ (1971) Statistical principles in experimental design. McGraw Hill, New York